We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal court has ruled that five patents on Santarus’ heartburn drug Zegerid are invalid due to obviousness, a move that could pave the way for
generic versions of the drug to enter the market.